Sutro Biopharma (STRO) Long-Term Debt Issuances (2020)
Sutro Biopharma recorded quarterly Long-Term Debt Issuances of $25.0 million in Q1 2020.
Sutro Biopharma's Long-Term Debt Issuances history runs 1 years deep, the most recent figure standing at $25.0 million for Q1 2020.
- In Q1 2020, Long-Term Debt Issuances changed N/A year-over-year to $25.0 million; the TTM figure through Dec 2020 stood at $25.0 million (changed N/A YoY), while the FY2020 annual figure was $25.0 million, changed N/A from the prior year.
- Long-Term Debt Issuances came in at $25.0 million for Q1 2020 at Sutro Biopharma.
- In the past five years, Long-Term Debt Issuances ranged from a high of $25.0 million in Q1 2020 to a low of $25.0 million in Q1 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 2.73 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Sutro Biopharma | 242.87 Mn | 242.87 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 25.00 Mn |
| Mar 31, 2020 | 25.00 Mn |